浙江震元(000705) - 2020 Q1 - 季度财报

Important Notice This section provides crucial declarations regarding the quarterly report's accuracy and the board's approval status Board Statement and Audit Opinion The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report, with all directors attending the review meeting, and the report remains unaudited - The company's board of directors, supervisory board, directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or material omissions[5] - All directors attended the board meeting to review this quarterly report[5] - This quarterly report has not received a non-standard audit opinion[5] Company Profile This section details the company's key financial performance and shareholder structure for the reporting period Key Accounting Data and Financial Indicators In Q1 2020, the company's operating revenue decreased by 1.85% year-on-year, and net profit attributable to shareholders decreased by 10.22%, with non-recurring net profit significantly down 55.43% due to CNY 8.4 million in non-recurring items like government grants and investment income | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | CNY 762,595,784.50 | CNY 776,992,792.79 | -1.85% | | Net Profit Attributable to Shareholders of Listed Company | CNY 14,596,215.38 | CNY 16,258,642.95 | -10.22% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | CNY 6,194,980.64 | CNY 13,899,867.29 | -55.43% | | Net Cash Flow from Operating Activities | CNY -120,777,772.38 | CNY -108,830,861.58 | -10.98% | | Basic Earnings Per Share (CNY/share) | 0.0437 | 0.0487 | -10.27% | | Total Assets | CNY 2,638,819,177.07 | CNY 2,588,554,088.01 | 1.94% (vs. end of prior year) | - During the reporting period, the company's total non-recurring gains and losses amounted to CNY 8,401,234.74, primarily comprising government grants (CNY 3.36 million), capital occupation fees (CNY 2.63 million), and wealth management income (CNY 2.01 million)[6][7] Shareholder Information As of the end of the reporting period, the company had 32,139 common shareholders, with Shaoxing Zhenyuan Health Industry Group Co., Ltd. (state-owned legal entity) as the largest shareholder holding 20.62%, and no significant related party relationships among the top ten shareholders - As of the end of the reporting period, the company had 32,139 common shareholders[9] | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Shaoxing Zhenyuan Health Industry Group Co., Ltd. | State-owned Legal Entity | 20.62% | 68,904,123 | | Shenzhen Zhongzhi Investment Co., Ltd. | Domestic General Legal Entity | 1.65% | 5,515,500 | | Jiang Shibo | Domestic Natural Person | 1.46% | 4,880,000 | Significant Matters This section outlines major financial changes and other important operational developments during the reporting period Analysis of Significant Changes in Key Financial Items During the reporting period, several financial items experienced significant changes, including a 43% decrease in monetary funds due to wealth management, a 103% increase in prepayments from business model shifts, a surge in short-term borrowings from new pandemic re-loans, a 99% rise in other payables from temporary pandemic material receipts, a 1236% increase in non-operating income from R&D grants, and a 369% expansion in net cash outflow from investing activities due to increased investment in Shaoxing Bank | Item | Change Rate | Explanation of Significant Change | | :--- | :--- | :--- | | Balance Sheet Items | | | | Monetary Funds | -43.03% | Due to Zhenyuan Pharmaceutical, a wholly-owned subsidiary, utilizing idle funds for wealth management | | Prepayments | 102.86% | Due to increased prepayment methods under the "Two-Invoice System" sales model and an increase in general agency product categories | | Short-term Borrowings | Not Applicable (Increased from 0) | Due to new pandemic re-loans | | Other Payables | 98.77% | Due to the company's temporary receipt of funds for pandemic prevention materials awaiting payment | | Income Statement Items | | | | Financial Expenses | -45.49% | Due to decreased interest expenses and reduced exchange gains/losses | | Other Income | 230.54% | Due to receipt of medical reserve funds | | Non-operating Income | 1235.73% | Due to Zhenyuan Pharmaceutical, a wholly-owned subsidiary, receiving technology R&D grants | | Cash Flow Statement Items | | | | Net Cash Flow from Investing Activities | -368.98% | Due to cash paid for capital increase and share expansion in Shaoxing Bank | | Net Cash Flow from Financing Activities | Not Applicable (Changed from negative to positive) | Due to an increase in pandemic re-loans | Other Significant Matters During the reporting period, the company used CNY 250 million of idle funds to purchase bank wealth management products, with no securities or derivatives investments, illegal guarantees, or share repurchases, and no occupation of funds by the controlling shareholder, nor any performance forecast for H1 2020 - The company had no overdue unfulfilled commitments during the reporting period[16] - The company did not provide a forecast for its operating performance for January-June 2020[17] - The company used CNY 250 million of its own idle funds to purchase bank wealth management products[18] - During the reporting period, the company had no illegal external guarantees or non-operating occupation of funds by the controlling shareholder[22][23] Financial Statements This section presents the company's unaudited financial statements for the first quarter of 2020, along with explanations of accounting policy changes and audit status Accounting Standard Changes and Adjustments The company adopted new revenue and lease standards from January 1, 2020, with no adjustments to the consolidated and parent company balance sheet items at the beginning of 2020 due to these accounting policy changes - The company first adopted new revenue and lease standards, but according to the disclosed adjustment table, the adjustment amount for relevant financial statement items as of January 1, 2020, was zero[25][26][27] Audit Opinion This company's first-quarter 2020 report is unaudited - The company's first-quarter report is unaudited[29] Key Financial Statements This section provides the company's unaudited consolidated and parent company balance sheets, income statements, and cash flow statements for Q1 2020, forming the basis for all financial data and analysis in this report - The report includes consolidated and parent company balance sheets as of March 31, 2020[32] - The report includes consolidated and parent company income statements for the first quarter of 2020[34] - The report includes consolidated and parent company cash flow statements for the first quarter of 2020[36]